Affordable Access

deepdyve-link
Publisher Website

Thymic Stromal Lymphopoietin and Cancer: Th2-Dependent and -Independent Mechanisms

Authors
  • Protti, Maria Pia1, 2
  • De Monte, Lucia1, 2
  • 1 Tumor Immunology Unit, Istituto di Ricerca a Carattere Scientifico (IRCCS), San Raffaele Scientific Institute, Milan , (Italy)
  • 2 Division of Immunology, Transplantation and Infectious Diseases, San Raffaele Scientific Institute, Milan , (Italy)
Type
Published Article
Journal
Frontiers in Immunology
Publisher
Frontiers Media SA
Publication Date
Sep 16, 2020
Volume
11
Identifiers
DOI: 10.3389/fimmu.2020.02088
PMID: 33042121
PMCID: PMC7524868
Source
PubMed Central
Keywords
License
Unknown

Abstract

The thymic stromal lymphopoietin (TSLP) is an IL-7-like cytokine originally cloned from a murine thymic stromal cell line, and subsequently a human homolog was identified using database search methods. Human TSLP is mostly expressed in epithelial cells, among which are keratinocytes as well as stromal cells such as fibroblasts and immune cells. Human TSLP was first described to activate myeloid dendritic cells, which prime naïve T helper cells to produce high concentrations of Th2 cytokines, thus representing a key cytokine in triggering dendritic cells-mediated allergic Th2 inflammation. TSLP and/or its receptor has been shown to be expressed in several tumor types, where TSLP expression is associated with functional activities that can be associated or not with the induction of a Th2-prone tumor microenvironment, i.e., Th2-dependent and Th2-independent mechanisms. These mechanisms involve tissue- and immune cell target-dependent tumor-promoting or tumor-suppressive functions in different or even the same tumor type. Here we report and discuss the Th2-dependent and Th2-independent roles of TSLP in cancer and possible therapeutic targeting.

Report this publication

Statistics

Seen <100 times